A
grade
Dengzhanxixin injection for acute ischemic stroke after reperfusion therapy: A double-blind, placebo-controlled, multi-center clinical trial.
CJC-1295 · IBRO neuroscience reports · 2026 · RCT · Phase 3 · n=246
Dengzhanxixin injection showed a non-significant trend towards improved outcomes in stroke patients post-reperfusion, with no increase in adverse events.
78.21% with mRS 0-1 at 90 days in high-dose group